ESRD: State of the Art and Charting the Challenges for the Future Beth Israel Deaconess and Harvard Medical School April 23 – 26, 2009 A teaching hospital.

Slides:



Advertisements
Similar presentations
The Nephrology Oral History Project
Advertisements

Risk Stratification in Renal Care Mary Jane McKendry Vice President, Operations Fresenius Disease Management Optimal Renal Care.
Christopher Keller, MD Director of Clinical Operations Boise Kidney and Hypertension Institute RPA 2011 Annual Meeting Friday, March 18, 2011.
The System Redesign Series: Patient-Centered Medical Homes (PCMH) Patient-Centered Medical Homes: “An approach to providing comprehensive primary care...
Chronic Kidney Disease and Dialysis Patient Care – What the Generalist Should Know Stephen R. Ash, MD, FACP Clarian Arnett Health Director of Dialysis,
The Medicare Modernization Act: One step forward or two steps back? Allen R. Nissenson MD Professor of Medicine Director, Dialysis Program David Geffen.
This Power Point presentation belongs to the Danish Renal Registry, which owns the copyright. It can be freely used for non-commercial study and educational.
Admission Patterns for Danish ESRD Patients DNS National Register and National Patient Register merged 9317 patients 232,760 admissions 167,217.
ESRD: State of the Art and Charting the Challenges for the Future Beth Israel Deaconess and Harvard Medical School April 23 – 26, 2009 A teaching hospital.
Patient and Family Group Meetings 2014 Quality Improvement Activity.
Chapter 12: USRDS Special Study Center on Transition of Care in CKD 2014 ANNUAL DATA REPORT VOLUME 1: CHRONIC KIDNEY DISEASE.
“Wireless Diabetes Program: A patient, hospital and primary care collaboration ” 8 th Annual INET Mini-Conference June Metro Toronto Convention.
Core Competencies Program POSTGRADUATE CORE COMPETENCY PROGRAM Sero Andonian, MD, MSc, FRCSC, FACS Director of Postgraduate Core Competencies Program July.
Living Donor Kidney Transplant. What does the evidence say about outcome ? Professor Peter J Conlon.
Infections in the dialysis population: A major communicable disease issue! Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director,
STRATEGY FOR MANAGEMENT OF ESRD IN MOROCCO K. Soulami Service de Néphrologie CHU Ibn Rochd, Casablanca ESPN, Lyon, September 11-14, 2008.
Individualizing Care in HIV: A Critical Review of Treatment Options Presented by The Johns Hopkins University School of Medicine Produced in collaboration.
MARC – Network 5 5 Diamond Patient Safety Program
Protein intake and phosphate control in renal care: international variations in trends and practice Elizabeth Lindley, 1 Maria Cruz Casal, 2 Susan Rogers,
Creating an Oligopoly in the Treatment of End Stage Renal Disease and the Subsequent Impact on Home Hemodialysis Therapies in the United States John D.
CHRONIC KIDNEY DISEASE National Healthcare Quality and Disparities Report Chartbook on Effective Treatment.
ISPOR POLAND CHAPTER Polish Society of Pharmacoeconomics (PTFe )
Doctors’ Ties to Drug Makers Are Put On Close View.
ISPOR Polish Chapter Accomplishments and plans for 2007/2008.
Polish Association of Dialyzed People In the year 2012 was released three issues of the magazine "Dialysis and You". In addition to making the current.
Partnerships between Nursing & Physician Associations: Maximizing Resources, Reach and Expertise Judy Lentz, RN, MSN, NHA Chief Executive Officer Hospice.
Demonstration projects and the future of care delivery and financing Allen R. Nissenson MD Professor of Medicine Director, Dialysis Program David Geffen.
The ESRD Network and a Patient’s Perspective on a Disaster Kidney & Urology Foundation of America NY Hall of Science Queens, NY June 19, 2007.
Review of literature and report of experience with erythropoietin in ESRD populations Summary to FDA Cardio Renal Committee J. Michael Lazarus, M.D. CMO.
Disclosure of Financial Conflicts of Interest in Continuing Medical Education Michael D. Jibson, MD, PhD and Jennifer Seibert, MD University of Michigan.
What did we learn from the 1989 Dallas Morbidity and Mortality Meeting? Alan R. Hull, MD A teaching hospital of Harvard Medical School.
National Capital of Healthcare Executives and George Mason University Proudly Present The Patient Protection and Affordability Care Act: Optimizing Opportunities.
Impact of Renal Transplantation on Psychosocial Status of HIV Positive Patients DR. Prof. D. K. AGARWAL MD,DM,DNB,MAMS,FICP,FISN Senior Consultant Nephrologist,
The Medicare crisis: What does it mean for nephrology care? Allen R. Nissenson MD Professor of Medicine Director, Dialysis Program David Geffen School.
Survival after graft failure Dr Lynsey Webb Registrar UK Renal Registry UK Renal Registry 2011 Annual Audit Meeting.
NYU Hospital for Joint Diseases NYU Langone Medical Center Fourth Annual Clinical Research Methodology Course Co-Sponsored by NYU Post-Graduate Medical.
Minority Affairs Committee Fall  Patient resource promoting early referral for transplant evaluation  Collaborated with Patient Affairs Committee.
Kidney disease burden and available Renal transplantation and Dialysis services in India Dr. Sham Sunder.
VIVA Health, Inc. Health Plan & Medical Home Benefit Information Session.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Similar Outcomes With Hemodialysis and Peritoneal.
Preemptive Kidney Transplant (PKT) – the Optimal Therapy in ESRD Reference: Connie L. Davis. Preemptive transplantation and the transplant first initiative.
World Kidney Day 2016: Kidney Disease & Children
Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Royal College of Physicians
Royal College of Physicians
National Trends in Emergency Medicine Residency ECG Curriculum and Interpretation Practices Céline Pascheles, MD, Leslie Bilello MD, Jenna Singleton MD,
Pneumococcal pneumonia vaccinations, by unit affiliation.
Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.
Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.
Effects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes  Eduardo Lacson, MD, MPH, Weiling Wang,
Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider’s Perspective  J. Michael Lazarus, MD, Raymond M. Hakim,
Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis Outcomes and Practice Patterns Study (DOPPS): Nutrition guidelines, indicators, and.
CanMEDS Roles Covered X
Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns.
Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought  Nicolas Rognant, Maurice Laville  Kidney.
Acute myocardial infarction in patients with end-stage renal disease
Volume 54, Issue 2, Pages (August 1998)
CanMEDS Roles Covered X
Daniel E. Weiner, MD, MS, Mark J. Sarnak, MD, MS 
Counteracting progression of renal disease: A look into the future
Michael J. Germain, MD, Sara N. Davison, MD, Alvin H. Moss, MD 
Varying Patterns of ESKD Care Globally: Achieving Equity
Restructuring the ESRD payment system in the United States
The Use of Vaccines in Adult Patients With Renal Disease
Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Mortality caused by cardiovascular disease (A) and sepsis (B) of patients with end-stage renal disease (ESRD) treated by dialysis compared with the general.
By estimating per-month expenditures for patients aged 45 to 64 as 85% of those documented in a 67-yr-old, it is possible to approximate the financial.
CanMEDS Roles Covered X
Presentation transcript:

ESRD: State of the Art and Charting the Challenges for the Future Beth Israel Deaconess and Harvard Medical School April 23 – 26, 2009 A teaching hospital of Harvard Medical School

Introductions Welcome and Outline: Making a Difference –Tom F. Parker lll –Theodore I. Steinman

A teaching hospital of Harvard Medical School Steering Committee Chairmen: Tom F. Parker and Theodore I. Steinman William M. Bennett, MD Allan J. Collins, MD Richard J. Cronin, MD Francis L. Delmonico, MD Raymond Hakim, MD William L. Henrich, MD Alan Hull, MD: –Honorary Chairman Prof. Norbert Lameire J. Michael Lazarus, MD Edmund Lowrie, MD Andrew S. Narva, MD Allen R. Nissenson, MD Eberhard Ritz, MD

A teaching hospital of Harvard Medical School Sponsors with appreciation Platinum Level –Amgen –Genzyme

A teaching hospital of Harvard Medical School Sponsors with appreciation Gold Level –Abbott Laboratories –American Renal Associates, LLC –Dallas Nephrology Associates, PA –Renal Ventures Management –Watson Pharmaceuticals

A teaching hospital of Harvard Medical School Sponsors with appreciation Silver Level –AMAG Pharmaceuticals, Inc –NxStage –U. S. Renal –Fresenius Medical Care, NA Contributors –B. Braun Medical, Inc. –DaVita

A teaching hospital of Harvard Medical School Program Endorsements American Society of Nephrology National Kidney Foundation Renal Physicians Association International Society of Nephrology European Dialysis and Transplant Association/European Renal Association

A teaching hospital of Harvard Medical School Purpose of the meeting Explore medical and non-medical determinants of outcomes in the ESRD population –Medical: state of art lectures that cover the issues impacting ESRD –Non-medical: Impact on outcomes of government regulations and payment, guidelines, insurance companies, dialysis providers…. Use the information to plan new care initiatives and opportunities

A teaching hospital of Harvard Medical School Knowledge has value only in so far as we can put it toward good purpose

A teaching hospital of Harvard Medical School Eugene O’Neill, a marvelous and controversial playwright, observed once that “There is no present or future, only the past happening over and over again.” Did he have RRT in mind when saying this.

A teaching hospital of Harvard Medical School The charge given to our speakers: Determine the accomplishments in ESRD RRT over the past 20 years Determine the impediments to improving RRT over the past 20 years Understand the science to further improve outcomes Understand the environment in which to apply the science Outline the best approaches for care over the next 5 years

A teaching hospital of Harvard Medical School The Setting Our Milieu –20% of facility patients die each year –A program that costs $34,000,000,000/year –$20,000 per patient per year in hospitalizations –Less than 20% rehabilitation –Survival results no better than colon ca. 104,000 new ESRD patients – 2005 –97,143 In Center HD –6875 PD –2424 Pre-emptive transplant

A teaching hospital of Harvard Medical School Is this the best that we can do?

A teaching hospital of Harvard Medical School Is the Problem? The Science The interpreter of the science –The nephrologist and other caregivers The dialysis service provider The patient –Demographics –Reluctance to participate in optimal care

A teaching hospital of Harvard Medical School Is the Problem? The payment system –Effect on innovation –Tenuous dependence EPOGEN Commercial payors –Medical Director conflicts of interest Guidelines

A teaching hospital of Harvard Medical School (Our) world is (what it is), not because of those who do bad things, but because of those who look on and do nothing." -Albert Einstein

A teaching hospital of Harvard Medical School The Historical Perspective Co-Chairs: Drs. Mark Zeidel and Sushrat Waiker 2:10 – 2:40 - What did we learn from the 1989 Dallas Conference on Mortality in Dialysis – Dr. Alan R. Hull